{"log_id": 275091337795911101, "direction": 0, "words_result_num": 35, "words_result": [{"probability": {"variance": 0.00065, "average": 0.980711, "min": 0.934728}, "location": {"width": 326, "top": 141, "height": 38, "left": 68}, "words": "【孕妇及哺乳期妇女用药】"}, {"probability": {"variance": 0.000669, "average": 0.974956, "min": 0.93068}, "location": {"width": 114, "top": 198, "height": 32, "left": 75}, "words": "妊娠用药"}, {"probability": {"variance": 0.01412, "average": 0.928368, "min": 0.496756}, "location": {"width": 1241, "top": 251, "height": 57, "left": 130}, "words": "在孕妇尚没与进行充分和良好对照的本品研究。但根据宾作用机制,孕好应用本品可能引起胎儿损"}, {"probability": {"variance": 0.031928, "average": 0.888456, "min": 0.367838}, "location": {"width": 1293, "top": 304, "height": 59, "left": 75}, "words": "。在低于人体暴露量的动物母体暴水平,依维莫司呼引起胚胎脸仔毒。如果妊期间应用该药在"}, {"probability": {"variance": 0.023774, "average": 0.918871, "min": 0.412131}, "location": {"width": 1293, "top": 358, "height": 59, "left": 75}, "words": "用药期间怀孕,应告知患者该药对儿的在危害。应建议育期女性在服用本品期间采取有效的避孕措"}, {"probability": {"variance": 0.017513, "average": 0.863966, "min": 0.605828}, "location": {"width": 297, "top": 413, "height": 38, "left": 73}, "words": "施,直至治疗结束后8周"}, {"probability": {"variance": 0, "average": 0.999706, "min": 0.999682}, "location": {"width": 54, "top": 470, "height": 32, "left": 75}, "words": "哺乳"}, {"probability": {"variance": 0.039026, "average": 0.857733, "min": 0.356943}, "location": {"width": 1241, "top": 523, "height": 59, "left": 125}, "words": "目前大知依维司是否被分泌至人乳中。进入大鼠乳的依莫司和/或其代谢产物的浓度比母体血清"}, {"probability": {"variance": 0.022566, "average": 0.927418, "min": 0.363685}, "location": {"width": 1291, "top": 578, "height": 57, "left": 75}, "words": "中商3.5倍。因许多药物均分泌至人乳汁中,依莫司有导致乳儿发生严不良反应的可能性,因此应根据"}, {"probability": {"variance": 0.008224, "average": 0.966003, "min": 0.597184}, "location": {"width": 669, "top": 633, "height": 45, "left": 70}, "words": "药物对母亲的重要性决定是否停止哺乳或停止药物治疗"}, {"probability": {"variance": 0.012878, "average": 0.933948, "min": 0.737396}, "location": {"width": 116, "top": 688, "height": 34, "left": 66}, "words": "生育能力"}, {"probability": {"variance": 0.011509, "average": 0.944868, "min": 0.524918}, "location": {"width": 1206, "top": 740, "height": 57, "left": 123}, "words": "尚知依维莫对男性和女性的生育能力的潜在影响。但是曾观察到闭经(包括维发性闭经】病例"}, {"probability": {"variance": 0.007477, "average": 0.955647, "min": 0.553637}, "location": {"width": 1053, "top": 795, "height": 54, "left": 121}, "words": "基于非床研究发现,使用本品治疗可能导致雄性生能力篷低(参见【药理毒理】"}, {"probability": {"variance": 0.012898, "average": 0.911552, "min": 0.699377}, "location": {"width": 155, "top": 909, "height": 32, "left": 54}, "words": "〖儿童用药】"}, {"probability": {"variance": 0.035823, "average": 0.819066, "min": 0.429678}, "location": {"width": 916, "top": 955, "height": 66, "left": 118}, "words": "对于晚期肾痛和晚期胰脓神经内分泌瘤,本晶暂无儿用药数捷4"}, {"probability": {"variance": 0.000107, "average": 0.971826, "min": 0.961461}, "location": {"width": 123, "top": 955, "height": 52, "left": 1028}, "words": "有限"}, {"probability": {"variance": 0.035929, "average": 0.885127, "min": 0.356906}, "location": {"width": 1241, "top": 1017, "height": 57, "left": 118}, "words": "本晶建议用一需要治疗干预包无法通过根治性手术切除的1岁的结性硬化症相关的室管膜下巨细泡"}, {"probability": {"variance": 0.011676, "average": 0.942154, "min": 0.575251}, "location": {"width": 717, "top": 1072, "height": 45, "left": 61}, "words": "至形细胞瘤儿童患,需要在有经验的专科医生导下使用"}, {"probability": {"variance": 0.013886, "average": 0.945333, "min": 0.439477}, "location": {"width": 1232, "top": 1126, "height": 54, "left": 114}, "words": "在二项临研究中观察到的持久的客缓解(通过室管膜下细胞星形细胞瘤瘤体积的缩小来判)"}, {"probability": {"variance": 0.027813, "average": 0.891042, "min": 0.452172}, "location": {"width": 1257, "top": 1179, "height": 57, "left": 59}, "words": "证明了本品治疗结节性硬化症相关的室管膜下巨纤胞星形细腹缩儿童患者的有效性(见【临床试验】"}, {"probability": {"variance": 0.031223, "average": 0.890065, "min": 0.417746}, "location": {"width": 1293, "top": 1234, "height": 57, "left": 59}, "words": "尚犬证明室管膜下细胞星形细包痛儿电患者能否获得疾病关症状改善和总生存期延长。本品对生长和青"}, {"probability": {"variance": 0.032792, "average": 0.901485, "min": 0.362666}, "location": {"width": 365, "top": 1291, "height": 41, "left": 59}, "words": "明发育的长期作用尚清楚"}, {"probability": {"variance": 0.020159, "average": 0.926625, "min": 0.448836}, "location": {"width": 1218, "top": 1346, "height": 52, "left": 109}, "words": "研究1是一项在儿童和成人患者中进行的随机、双育、多中心研究,以对比本品(n=78)与安慰剂(nm39)"}, {"probability": {"variance": 0.015729, "average": 0.915788, "min": 0.483614}, "location": {"width": 1266, "top": 1398, "height": 57, "left": 57}, "words": "患者的中位年龄为9.5岁4范用0.8~26岁)。花隐机时,共有20名患为<3岁,54名患者为3至<12岁"}, {"probability": {"variance": 0.021402, "average": 0.901421, "min": 0.385073}, "location": {"width": 1296, "top": 1456, "height": 54, "left": 54}, "words": "27名患者为12至<18岁,106名者为18岁。除了<3岁年龄组的严重不良事件一感染的人均发生率"}, {"probability": {"variance": 0.023835, "average": 0.923366, "min": 0.384059}, "location": {"width": 1291, "top": 1510, "height": 54, "left": 57}, "words": "高以外,所有年龄组的其它药物不良反应的整体性质、类型和发生频本相假有3岁年龄组中,13名采用"}, {"probability": {"variance": 0.01475, "average": 0.936191, "min": 0.519957}, "location": {"width": 1296, "top": 1565, "height": 54, "left": 54}, "words": "本品治疗思者中共有6名(46%)发生至少一次因感染导致的严重不良事件,而7名安慰剂治疗患者中有2"}, {"probability": {"variance": 0.014138, "average": 0.940035, "min": 0.495998}, "location": {"width": 1293, "top": 1620, "height": 54, "left": 52}, "words": "名(29%)。任何年龄组中均未见感染而终止本品的治疗(参见【不昆反应】)。组分析显示:在接受"}, {"probability": {"variance": 0.003282, "average": 0.971268, "min": 0.725661}, "location": {"width": 859, "top": 1675, "height": 48, "left": 50}, "words": "本品治疗的所有儿童年龄亚组中,室管膜下巨细胞星形细胞瘤体积缩小"}, {"probability": {"variance": 0.012586, "average": 0.942993, "min": 0.404833}, "location": {"width": 1234, "top": 1730, "height": 52, "left": 102}, "words": "研究2是一项在≥3岁患者中进行的开放,单组、单中心的究(N=28):患者的中位龄为11岁("}, {"probability": {"variance": 0.019532, "average": 0.926375, "min": 0.394725}, "location": {"width": 1293, "top": 1783, "height": 57, "left": 48}, "words": "围3-34岁。共有16名息者为3至<12岁,6名思者为12至<18岁。6名患者为三18岁。不良反应的发生"}, {"probability": {"variance": 0.00611, "average": 0.957358, "min": 0.566424}, "location": {"width": 1291, "top": 1837, "height": 57, "left": 50}, "words": "频率在各年龄组之间基本相似(参见【不良反应】)。分析显示,在接受本品治疗的所有儿童年龄亚组"}, {"probability": {"variance": 0.007849, "average": 0.951736, "min": 0.696598}, "location": {"width": 496, "top": 1895, "height": 45, "left": 48}, "words": "中,室管膜下巨细胞星形细胞瘤体积缩小"}, {"probability": {"variance": 0.01003, "average": 0.95517, "min": 0.447807}, "location": {"width": 1241, "top": 1952, "height": 52, "left": 98}, "words": "根据体表面积标准化后的依维莫司清除率,对比结果为室管膜下巨细胞星形细胞瘤儿科患者高于成人患"}, {"probability": {"variance": 0.026993, "average": 0.897191, "min": 0.354406}, "location": {"width": 1293, "top": 2007, "height": 52, "left": 45}, "words": "者(参见【药代动力学】)无论是室管膜下细胞形细胞猪成点或儿科患者,都桌求按推荐的起始剂量"}], "language": 3}